PE20130601A1 - Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa - Google Patents
Formulacion de polvo seco que comprende un inhidor de fosfodiesterasaInfo
- Publication number
- PE20130601A1 PE20130601A1 PE2013000155A PE2013000155A PE20130601A1 PE 20130601 A1 PE20130601 A1 PE 20130601A1 PE 2013000155 A PE2013000155 A PE 2013000155A PE 2013000155 A PE2013000155 A PE 2013000155A PE 20130601 A1 PE20130601 A1 PE 20130601A1
- Authority
- PE
- Peru
- Prior art keywords
- cyclopropylmetoxy
- halogen
- optionally substituted
- phosphodiesterase
- dry powder
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA DE POLVO SECO INHALABLE QUE COMPRENDE: A) UN INHIBIDOR DE FOSFODIESTERASA 4 (PDE4) EN LA FORMA DE ENANTIOMERO (-) DE FORMULA (I) DONDE R1 Y R2 SON CADA UNO OR3, HNSO2R4 O ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALOGENO, EN DONDE R3 ES ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALOGENO O CICLOALQUILO(C3-C7); R4 ES ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO CON HALOGENO; n ES 0 O 1; SIENDO COMPUESTOS PREFERIDOS: 1-(3-CICLOPROPILMETOXI-4-DIFLUOROMETOXI-FENIL)-2-(3,5-DICLORO-PIRIDIN-4-IL)-ETIL ESTER DEL ACIDO (-)-3-CICLOPROPILMETOXI-4-METANSULFONILAMINO-BENZOICO, 1-(3-CICLOPROPILMETOXI-4-DIFLUOROMETOXI-FENIL)-2-(3,5-DICLORO-1-OXI-PIRIDIN-4-IL)-ETIL ESTER DEL ACIDO (-)-3-CICLOPROPILMETOXI-4-METANSULFONILAMINO-BENZOICO, ENTRE OTROS; B) UN VEHICULO FARMACOLOGICAMENTE INERTE TAL COMO LACTOSA; Y C) UN LUBRICANTE TAL COMO ESTEARATO DE MAGNESIO EN UNA CANTIDAD DE 0,01% A 2% EN PESO DE LA COMPOSICION. DICHA COMPOSICION FARMACEUTICA ES UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, ASMA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10171748 | 2010-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130601A1 true PE20130601A1 (es) | 2013-05-30 |
Family
ID=43262631
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001245A PE20171256A1 (es) | 2010-08-03 | 2011-07-27 | Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa |
| PE2013000155A PE20130601A1 (es) | 2010-08-03 | 2011-07-27 | Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001245A PE20171256A1 (es) | 2010-08-03 | 2011-07-27 | Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US9132121B2 (es) |
| EP (2) | EP2600830B1 (es) |
| JP (1) | JP6004233B2 (es) |
| KR (1) | KR101805958B1 (es) |
| CN (2) | CN103052379A (es) |
| AR (1) | AR082443A1 (es) |
| AU (1) | AU2011287711B2 (es) |
| BR (1) | BR112013002506A2 (es) |
| CA (1) | CA2807256C (es) |
| CL (1) | CL2013000293A1 (es) |
| CO (1) | CO6690744A2 (es) |
| CY (1) | CY1120605T1 (es) |
| DK (1) | DK2600830T3 (es) |
| EA (2) | EA024922B1 (es) |
| ES (1) | ES2664175T3 (es) |
| GE (1) | GEP20156343B (es) |
| HR (1) | HRP20180717T1 (es) |
| HU (1) | HUE037620T2 (es) |
| IL (1) | IL224517B (es) |
| LT (1) | LT2600830T (es) |
| MA (1) | MA34449B1 (es) |
| ME (1) | ME03022B (es) |
| MX (1) | MX346424B (es) |
| MY (1) | MY179703A (es) |
| NO (1) | NO2600830T3 (es) |
| NZ (1) | NZ606548A (es) |
| PE (2) | PE20171256A1 (es) |
| PH (1) | PH12013500235A1 (es) |
| PL (1) | PL2600830T3 (es) |
| PT (1) | PT2600830T (es) |
| RS (1) | RS57061B1 (es) |
| SG (1) | SG187258A1 (es) |
| SI (1) | SI2600830T1 (es) |
| TR (1) | TR201807012T4 (es) |
| UA (1) | UA112296C2 (es) |
| WO (1) | WO2012016889A2 (es) |
| ZA (1) | ZA201300870B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
| WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| EP3143987A1 (en) | 2010-08-03 | 2017-03-22 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
| JP2014518203A (ja) | 2011-06-06 | 2014-07-28 | キエスィ ファルマチェウティチ エス．ピー．エー． | ホスホジエステラーゼ阻害剤としての１−フェニル−２−ピリジニルアルキルアルコール誘導体 |
| KR20150079745A (ko) | 2012-11-08 | 2015-07-08 | 리젠 파마슈티컬스 소시에떼 아노님 | Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물 |
| EP2968204B1 (en) * | 2013-03-15 | 2019-05-15 | Robert I. Henkin | Phosphodiesterase inhibitors for treating taste and smell disorders |
| US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| RU2682660C9 (ru) | 2013-10-22 | 2019-06-21 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ получения ингибитора PDE4 |
| EP3082428A4 (en) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| CN104800192A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入粉雾剂及制备方法 |
| US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
| EP3166641B1 (en) | 2014-07-09 | 2018-09-12 | Arven Ilac Sanayi Ve Ticaret A.S. | A process for the preparation of formulations for inhalation |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| US10583085B2 (en) * | 2017-05-17 | 2020-03-10 | Chiesi Farmaceutici S.P.A. | Carrier particles for dry powder formulations for inhalation |
| WO2023117985A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
| KR20250006225A (ko) | 2022-04-27 | 2025-01-10 | 키에시 파르마슈티시 엣스. 피. 에이. | Pde4 억제제의 결정형 |
| WO2024027901A1 (en) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Predictive biomarker of clinical response to a pde4 inhibitor |
| AU2023347028A1 (en) | 2022-09-22 | 2025-05-01 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
| IL319640A (en) | 2022-09-22 | 2025-05-01 | Chiesi Farm Spa | Capsule inhaler for administration of a phosphodiesterase-4 inhibitor |
| CN119923250A (zh) | 2022-09-22 | 2025-05-02 | 奇斯药制品公司 | 用于施用磷酸二酯酶-4抑制剂的胶囊吸入器 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19841248A1 (de) | 1997-09-12 | 1999-04-29 | Fraunhofer Ges Forschung | Demonstrationseinrichtung in Form eines Lebewesens |
| DE59801018D1 (de) | 1997-09-16 | 2001-08-16 | Trench Switzerland Ag Basel | Spannungsteiler |
| TR200102567T2 (tr) | 1999-03-05 | 2002-01-21 | Chiesi Farmaceutici S.P.A. | İnhalasyon için geliştirilmiş toz halindeki farmasötik bileşimler |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| IL153705A0 (en) | 2000-06-27 | 2003-07-06 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
| US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| SI1658872T2 (sl) | 2002-07-31 | 2019-12-31 | Chiesi Farmacetuici S.P.A. | Inhalator prahu |
| DE10255387A1 (de) * | 2002-11-28 | 2004-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Tiotropium-haltige Pulverformulierung für die Inhalation |
| GB0326632D0 (en) * | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| CA2608837C (en) * | 2005-06-06 | 2011-08-02 | F. Hoffmann-La Roche Ag | Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l-cpt1) inhibitors |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP2022783A1 (en) * | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| EP2070913A1 (en) * | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| EP3143987A1 (en) | 2010-08-03 | 2017-03-22 | CHIESI FARMACEUTICI S.p.A. | Pharmaceutical formulation comprising a phosphodiesterase inhibitor |
| JP2014518203A (ja) | 2011-06-06 | 2014-07-28 | キエスィ ファルマチェウティチ エス．ピー．エー． | ホスホジエステラーゼ阻害剤としての１−フェニル−２−ピリジニルアルキルアルコール誘導体 |
| RU2682660C9 (ru) | 2013-10-22 | 2019-06-21 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Способ получения ингибитора PDE4 |
-
2011
- 2011-07-27 CN CN2011800382903A patent/CN103052379A/zh active Pending
- 2011-07-27 CA CA2807256A patent/CA2807256C/en active Active
- 2011-07-27 NZ NZ606548A patent/NZ606548A/en unknown
- 2011-07-27 EA EA201390049A patent/EA024922B1/ru unknown
- 2011-07-27 PE PE2017001245A patent/PE20171256A1/es unknown
- 2011-07-27 MX MX2013001172A patent/MX346424B/es active IP Right Grant
- 2011-07-27 SG SG2013008107A patent/SG187258A1/en unknown
- 2011-07-27 DK DK11741172.8T patent/DK2600830T3/en active
- 2011-07-27 MA MA35635A patent/MA34449B1/fr unknown
- 2011-07-27 BR BR112013002506A patent/BR112013002506A2/pt not_active Application Discontinuation
- 2011-07-27 UA UAA201302607A patent/UA112296C2/uk unknown
- 2011-07-27 PE PE2013000155A patent/PE20130601A1/es active IP Right Grant
- 2011-07-27 AU AU2011287711A patent/AU2011287711B2/en active Active
- 2011-07-27 EP EP11741172.8A patent/EP2600830B1/en active Active
- 2011-07-27 TR TR2018/07012T patent/TR201807012T4/tr unknown
- 2011-07-27 NO NO11741172A patent/NO2600830T3/no unknown
- 2011-07-27 PL PL11741172T patent/PL2600830T3/pl unknown
- 2011-07-27 PH PH1/2013/500235A patent/PH12013500235A1/en unknown
- 2011-07-27 RS RS20180394A patent/RS57061B1/sr unknown
- 2011-07-27 MY MYPI2013000339A patent/MY179703A/en unknown
- 2011-07-27 GE GEAP201112988A patent/GEP20156343B/en unknown
- 2011-07-27 ES ES11741172.8T patent/ES2664175T3/es active Active
- 2011-07-27 WO PCT/EP2011/062872 patent/WO2012016889A2/en active Application Filing
- 2011-07-27 PT PT117411728T patent/PT2600830T/pt unknown
- 2011-07-27 KR KR1020137002872A patent/KR101805958B1/ko active Active
- 2011-07-27 EP EP17176635.5A patent/EP3246016B1/en active Active
- 2011-07-27 ME MEP-2018-101A patent/ME03022B/me unknown
- 2011-07-27 CN CN201710259305.8A patent/CN106890165A/zh active Pending
- 2011-07-27 LT LTEP11741172.8T patent/LT2600830T/lt unknown
- 2011-07-27 JP JP2013522202A patent/JP6004233B2/ja active Active
- 2011-07-27 HU HUE11741172A patent/HUE037620T2/hu unknown
- 2011-07-27 EA EA201690541A patent/EA027692B1/ru unknown
- 2011-07-27 SI SI201131448T patent/SI2600830T1/en unknown
- 2011-08-02 US US13/195,885 patent/US9132121B2/en active Active
- 2011-08-02 AR ARP110102782 patent/AR082443A1/es not_active Application Discontinuation
-
2013
- 2013-01-30 CL CL2013000293A patent/CL2013000293A1/es unknown
- 2013-01-31 IL IL224517A patent/IL224517B/en active IP Right Grant
- 2013-02-01 CO CO13019325A patent/CO6690744A2/es unknown
- 2013-02-01 ZA ZA2013/00870A patent/ZA201300870B/en unknown
-
2015
- 2015-08-07 US US14/820,939 patent/US9308200B2/en active Active
-
2018
- 2018-03-09 CY CY181100288T patent/CY1120605T1/el unknown
- 2018-05-09 HR HRP20180717TT patent/HRP20180717T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130601A1 (es) | Formulacion de polvo seco que comprende un inhidor de fosfodiesterasa | |
| PE20120055A1 (es) | (1-fenil-2-piridin-4-il)etil esteres del acido benzoico como inhibidores de fosfodiesterasa | |
| CY1123365T1 (el) | Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
| CR9832A (es) | Compuestos de pirimidina amida como inhibidores de pgds | |
| MD4556C1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| CL2015001148A1 (es) | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por cftr | |
| PE20170502A1 (es) | ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6 | |
| PE20120989A1 (es) | Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo | |
| CL2016000187A1 (es) | Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad antagonista de receptores muscarínicos así como actividad agonista del receptor b2 adrenérgico. | |
| PE20141964A1 (es) | Formulaciones farmaceuticas novedosas | |
| MA34069B1 (fr) | Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a) | |
| PA8848201A1 (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
| IN2014DN09352A (es) | ||
| IN2014DN09348A (es) | ||
| PE20161218A1 (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR080792A1 (es) | Compuesto de 1-acetil-indol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para la inhibicion de la actividad de perk y para tratar o reducir la gravedad del cancer y otras dolencias. | |
| CY1116892T1 (el) | Ενωσεις οι οποιες εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
| PH12013502463A1 (en) | Trpv4 antagonists | |
| AR080746A1 (es) | (r)-n-(3-(7-metil-1h-indazol-5-il)1-(4-(1-metilpiperidin-4-il)piperazin-1-il)-1-oxopropan-2-il)-4-(2-oxo-1,2-dihidroquinolin-3-il)piperidina-1-carboxamida antagonista de receptores cgrp. | |
| CO6351778A2 (es) | Acidos naftilaceticos | |
| PE20130236A1 (es) | Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo | |
| ATE538100T1 (de) | Aminotetrahydroindazoloessigsäuren | |
| PE20142318A1 (es) | Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona | |
| PE20142445A1 (es) | Compuestos de pirazol sustituidos como antagonistas de lpar | |
| CL2011002461A1 (es) | Compuestos derivados de tipo amida de compuestos [3,2-c] pirazol con actividad glucocorticoide utiles en condiciones inflamatorias y alergicas como asma, epoc o rinitis alergica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal | ||
| AE | Restoration of lapsed or forfeited application | ||
| FG | Grant, registration |